Dumesnil Simon 4

What Happened
Simon Dumesnil, a director of Pasithea Therapeutics Corp. (KTTA), was granted an equity award on 2026-05-01 covering 152,783 shares (reported as a derivative award). The filing lists the acquisition price as $0.00 and a reported value of $0 — this is a grant under the company’s equity plan, not a cash purchase or sale.

Key Details

• Transaction date: 2026-05-01 (Form 4 filed 2026-05-05).
• Transaction type/code: Award/Grant (A) of 152,783 shares; price reported $0.00; reported value $0 (derivative).
• Shares owned after transaction: Not specified in the supplied summary of the filing.
• Vesting and plan terms (footnote): Award made under the 2023 Stock Incentive Plan; shares underlying the option vest in full on the one-year anniversary of the grant if the reporting person remains a director, and will fully vest upon a Change in Control.
• Filing timeliness: Form 4 was filed May 5 for a May 1 grant — this is one business-day late relative to the standard two-business-day Form 4 deadline.

Context
This was an equity grant (compensation) rather than an open-market buy or sale. No cash was exchanged at grant and the shares are subject to vesting conditions, so this does not represent an immediate increase in tradable shares. Such awards are common for directors as part of compensation and do not by themselves indicate a personal purchase or sale decision.